The findings that the acute insulinotropic actions of GLP-1, but not GIP, were relatively preserved in people with type 2 diabetes (T2D) (2) focused greater attention on the therapeutic potential of GLP-1, ultimately supporting multiple clinical development programs for GLP-1 receptor (GLP-1R) agonists (GLP-1RA). This evidence concerns the gene GIP and type 2 diabetes mellitus.